Matched preclinical designs for improved translatability

Matched preclinical designs for improved translatability

May 10, 2017

A more stratified preclinical design strategy will increase the statistical power and reproducibility of animal studies and their translatability.

View Details

F1000 Research - Reproducibility2020: Progress and priorities

Reproducibility2020: Progress and priorities

May 2, 2017

The preclinical research process is a cycle of idea generation, experimentation, and reporting of results. The biomedical research community relies…

View Details

A journalist shines a harsh spotlight on biomedicine’s reproducibility crisis

A journalist shines a harsh spotlight on biomedicine’s reproducibility crisis

April 3, 2017

View Details

Asilomar Antibody Workshop Report

GBSI

December 20, 2016

The Antibody Validation: Standards, Policies, and Practices Workshop took place from September 25-27th in Pacific Grove, California at the historic…

View Details

Proficiency Index Assessment (PIA)

GBSI

December 16, 2016

Every year $28B is spent on preclinical research that cannot be reproduced, a challenge that increases the cost and time…

View Details

The Drive for Antibody Standards—Time to Herd the Cats

GEN: Genetic Engineering & Biotechnology News (scroll to end of featured article)

December 1, 2016

Dr. Freedman's commentary can be found at end of the Feature Article by Dee Ann Visk Imagine that you have…

View Details

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2

BioProcess International

November 14, 2016

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 2 -…

View Details

Biosimilar Therapeutic Monoclonal Antibodies: Gaps in Science Limit Development of an Industry Standard for Their Regulatory Approval, Part 1

BioProcess International

October 14, 2016

Biosimilars are biologically derived pharmaceuticals intended to have clinical similarity to a legally marketed innovator product when that product’s patent…

View Details

The need for improved education and training in research antibody usage and validation practices

BioTechniques

June 30, 2016

Antibodies are indispensable biological reagents, yet are a major contributor to the current reproducibility crisis in preclinical research. Research antibodies…

View Details

We're wasting a lot of research funding using the wrong cell lines. Here's one thing we can do.

Retraction Watch

December 9, 2015

As new frontiers of science emerge, from Pluto to proteins, the very cornerstone of the scientific process—reproducibility—has also reared its…

View Details

The culture of cell culture practices and authentication—Results from a 2015 Survey

BioTechniques

October 13, 2015

Concerns continue to grow regarding irreproducible basic biological and preclinical research. In order to understand the extent of cell line…

View Details

Changing the Culture of Cell Culture: Applying Best Practices and Authentication to Ensure Scientific Reproducibility

Changing the Culture of Cell Culture: Applying Best Practices and Authentication to Ensure Scientific Reproducibility

October 1, 2015

Irreproducible preclinical research is a global, expensive, and well-recognized problem that contributes to delays and increased costs of drug discovery.…

View Details

Know Thy Cells: Improving Biomedical Research Reproducibility

Science Translational Medicine

July 1, 2015

As with all science, translational research builds on published studies. However, the alarm has been sounded on irreproducible basic and…

View Details

Irreproducibility: A $28B/Year Problem with some Tangible Solutions

Genetic Engineering News

June 30, 2015

By now, most scientists are familiar with the global and enormously expensive problem of irreproducible biomedical research. Conservatively, 50% or…

View Details

The Economics of Reproducibility in Preclinical Research

PLOS Biology

June 9, 2015

BACKGROUND Why do this study? The research community knows there is a problem with reproducibility. We wanted to put the…

View Details

Reproducibility: Changing the Policies and Culture of Cancer Cell Line Authentication

Nature Methods

May 28, 2015

Cancer cell lines have been used for decades in biomedical research. Cell line misidentification and contamination are among the most…

View Details

Cell line authentication to improve preclinical cancer research: Policies and training

AACR Annual Meeting Education Book

April 18, 2015

The Global Biological Standards Institute (GBSI), a Washington, D.C.-based nonprofit, is leading a multipartner effort to build awareness among cancer…

View Details

Antibodies: Validate recombinants too

Nature Correspondence

February 26, 2015

Recombinant antibodies are pure proteins with minimal batch-to-batch variability, so could provide an important element of antibody standardization (A. Bradbury…

View Details

The Impact of Preclinical Irreproducibility on Drug Development

Clinical Pharmacology & Therapeutics

December 2, 2014

The development of novel therapeutics builds upon the reproducibility of previously published data. Yet irreproducibility is pervasive in preclinical life…

View Details

The Increasing Urgency for Standards in Basic Biologic Research

Cancer Research

July 17, 2014

Dr. Freedman (GBSI) and Dr. Inglese (NCATS) show how irreproducible preclinical research can be traced to an absence of a…

View Details

Reproducibility: Life sciences lag in stringent standards

Nature Correspondance

December 19, 2013

Initiatives to ensure scientific reproducibility in life-science research should demand strict standards, such as the use of only authenticated cell…

View Details

The Case for Biological Standards

GBSI White Paper

December 11, 2013

The Case, prepared by independent consultants Health Advances and Feinstein Kean Healthcare, presents the latest findings on irreproducibility obtained from…

View Details